Comparative Pharmacology
Head-to-head clinical analysis: NEOSAR versus TEMOZOLOMIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NEOSAR versus TEMOZOLOMIDE.
NEOSAR vs TEMOZOLOMIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Alkylating agent that inhibits DNA replication and transcription by cross-linking DNA strands, leading to cell cycle arrest and apoptosis.
Temozolomide is an alkylating agent that causes DNA methylation at O6 and N7 positions of guanine, leading to DNA damage and apoptosis. It is converted to the active metabolite MTIC under physiological conditions.
Cyclophosphamide 500-1500 mg/m² IV every 2-4 weeks; oral 50-200 mg daily.
150 mg/m2 orally once daily for 5 consecutive days of a 28-day cycle; for first cycle, then increase to 200 mg/m2/day if tolerated.
None Documented
None Documented
Terminal elimination half-life: 3-5 hours; prolonged in hepatic impairment (up to 12 hours).
Clinical Note
moderateTemozolomide + Digoxin
"Temozolomide may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateTemozolomide + Digitoxin
"Temozolomide may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderateTemozolomide + Deslanoside
"Temozolomide may decrease the cardiotoxic activities of Deslanoside."
Clinical Note
moderateTemozolomide + Acetyldigitoxin
"Temozolomide may decrease the cardiotoxic activities of Acetyldigitoxin."
1.8 hours (range 1.3–2.5 hours) for temozolomide; the active monomethyl triazeno imidazole carboxamide (MTIC) metabolite has a half-life of approximately 2.0 hours.
Renal: 30-60% unchanged; biliary/fecal: 10-20% as metabolites.
Approximately 38% of total radioactivity is excreted in urine over 7 days (5.6% as unchanged temozolomide, 12% as AIC metabolite, 21% as other polar metabolites), and less than 1% is excreted in feces.
Category C
Category D/X
Alkylating Agent
Alkylating Agent